Evidence map›Paper›PMID 34201707›Full record

ArticleCancers2021

Establishment of a Pretreatment Nomogram to Predict the 6-Month Mortality Rate of Patients with Advanced Biliary Tract Cancers Undergoing Gemcitabine-Based Chemotherapy.

Chiao-En Wu, Wen-Kuan Huang, Wen-Chi Chou, Chia-Hsun Hsieh, John Wen-Cheng Chang, Cheng-Yu Lin, Chun-Nan Yeh, Jen-Shi Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chiao-En WuDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.ORCID 0000-0002-1081-8805
Wen-Kuan HuangDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.ORCID 0000-0001-7789-8347
Wen-Chi ChouDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.
Chia-Hsun HsiehDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.
John Wen-Cheng ChangDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.
Cheng-Yu LinDepartment of Gastroenterology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.
Chun-Nan YehDepartment of General Surgery, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.ORCID 0000-0003-1455-092X
Jen-Shi ChenDepartment of Internal Medicine, Division of Haematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine, Chang Gung University, 333 Taoyuan, Taiwan.ORCID 0000-0001-9756-3974
Chang Gung University · TW

Funding

Chang Gung Memorial Hospital CMRPG3K0601, CMRPG3J0971~2, and CRRPG3K0021~2 to CEW; CMRPG3I0241~3 and CRRPG3K0031~2 to CNYMinistry of Science and Technology 109-2314-B-182-080-MY3 to CEW
6 · The paper itself

Abstract

backgroundThe estimation of mortality risk among patients diagnosed with advanced cancer provides important information for clinicians and patients in clinical practice. Currently, gemcitabine-based chemotherapy regimens are the standard treatment for patients with advanced biliary tract cancer (BTC). We aimed to develop a nomogram to predict the 6-month mortality rate among patients with advanced BTC to help physicians evaluate treatment options and outcomes. PATIENTS: We conducted a retrospective analysis to evaluate the 6-month mortality rate among patients with advanced BTC who underwent gemcitabine-based chemotherapy from 2012 to 2018. Data regarding pretreatment factors and the clinical response to treatment were collected. Univariate and multivariate analyses were performed to identify independent factors for nomogram creation.

resultsA total of 202 advanced BTC patients who were treated with gemcitabine-based chemotherapy were included in this analysis. No difference in survival was identified between patients undergoing gemcitabine monotherapy and those treated with gemcitabine combined with other cytotoxic agents. The univariate analysis revealed 10 significant factors, while the multivariate analysis identified four independent factors, including gender, monocyte to lymphocyte ratio (MLR), alkaline phosphatase (ALP), and liver metastasis, which were used to establish the nomogram. The performance of this nomogram for the prediction of 6-month mortality risk was found to be promising and feasible based on logistic regression.

conclusionA nomogram based on four independent pretreatment factors, including gender, MLR, ALP, and liver metastasis, was established to predict the 6-month mortality risk in patients with advanced BTC; it can provide clinicians and patients with additional information when evaluating treatment outcomes.

Indexed as

biliary tract cancerchemotherapygemcitabinenomogramprognostic factors

Identifiers

PMID34201707
PMCPMC8268608
OpenAlexW3173173860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.